Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis

BACKGROUND: Pancreatic cancer is considered as a chemoresistant neoplasm with extremely dismal prognosis. Gemcitabine is recommended as the standard agent for locally advanced or metastatic pancreatic cancer. A series of trials have been conducted to improve the outcome of advanced pancreatic cancer...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Drug Des Devel Ther
Hlavní autoři: Wang, Yuan, Hu, Guo-fang, Zhang, Qian-qian, Tang, Ning, Guo, Jun, Liu, Li-yan, Han, Xiao, Wang, Xia, Wang, Zhe-hai
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2016
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4912328/
https://ncbi.nlm.nih.gov/pubmed/27358556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S105442
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky